KR102675966B1 - Composition for preventing hair loss and promoting hair growth - Google Patents
Composition for preventing hair loss and promoting hair growth Download PDFInfo
- Publication number
- KR102675966B1 KR102675966B1 KR1020210092451A KR20210092451A KR102675966B1 KR 102675966 B1 KR102675966 B1 KR 102675966B1 KR 1020210092451 A KR1020210092451 A KR 1020210092451A KR 20210092451 A KR20210092451 A KR 20210092451A KR 102675966 B1 KR102675966 B1 KR 102675966B1
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- hair
- promoting
- adenosine
- panthenol
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 122
- 230000003779 hair growth Effects 0.000 title claims abstract description 70
- 230000001737 promoting effect Effects 0.000 title claims abstract description 54
- 230000003658 preventing hair loss Effects 0.000 title claims abstract description 42
- 230000000694 effects Effects 0.000 claims abstract description 41
- 230000002500 effect on skin Effects 0.000 claims abstract description 21
- 239000004480 active ingredient Substances 0.000 claims abstract description 17
- 108060000903 Beta-catenin Proteins 0.000 claims abstract description 14
- 102000015735 Beta-catenin Human genes 0.000 claims abstract description 14
- 230000002438 mitochondrial effect Effects 0.000 claims abstract description 7
- 230000011664 signaling Effects 0.000 claims abstract description 7
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 126
- 210000004209 hair Anatomy 0.000 claims description 81
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 72
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 66
- 239000011703 D-panthenol Substances 0.000 claims description 66
- 235000004866 D-panthenol Nutrition 0.000 claims description 66
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 65
- 229960003949 dexpanthenol Drugs 0.000 claims description 65
- 235000005152 nicotinamide Nutrition 0.000 claims description 64
- 239000011570 nicotinamide Substances 0.000 claims description 64
- 229960003966 nicotinamide Drugs 0.000 claims description 64
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 63
- 229960005305 adenosine Drugs 0.000 claims description 63
- 239000009141 Houttuynia cordata plant extract Substances 0.000 claims description 50
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 36
- 229960004889 salicylic acid Drugs 0.000 claims description 36
- 229940043810 zinc pyrithione Drugs 0.000 claims description 33
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 claims description 33
- 210000004761 scalp Anatomy 0.000 claims description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 15
- 235000015961 tonic Nutrition 0.000 claims description 15
- 230000001256 tonic effect Effects 0.000 claims description 15
- -1 packs Substances 0.000 claims description 8
- 239000002537 cosmetic Substances 0.000 claims description 7
- 239000006210 lotion Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 3
- 239000003921 oil Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000003599 detergent Substances 0.000 claims description 2
- 239000000686 essence Substances 0.000 claims description 2
- 239000000118 hair dye Substances 0.000 claims description 2
- 239000002453 shampoo Substances 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 229960000716 tonics Drugs 0.000 claims description 2
- 238000005728 strengthening Methods 0.000 claims 1
- 239000004615 ingredient Substances 0.000 abstract description 11
- 230000002195 synergetic effect Effects 0.000 abstract description 8
- 230000003656 anti-hair-loss Effects 0.000 abstract description 3
- 230000001747 exhibiting effect Effects 0.000 abstract description 2
- 201000004384 Alopecia Diseases 0.000 description 31
- 239000000284 extract Substances 0.000 description 26
- 230000003676 hair loss Effects 0.000 description 26
- 208000024963 hair loss Diseases 0.000 description 26
- 210000003491 skin Anatomy 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 238000009472 formulation Methods 0.000 description 15
- 238000011282 treatment Methods 0.000 description 13
- 108050003627 Wnt Proteins 0.000 description 12
- 102000013814 Wnt Human genes 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 11
- 210000003780 hair follicle Anatomy 0.000 description 11
- 240000000691 Houttuynia cordata Species 0.000 description 10
- 235000013719 Houttuynia cordata Nutrition 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 239000010865 sewage Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 230000003698 anagen phase Effects 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 235000013376 functional food Nutrition 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 230000003778 catagen phase Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241001289529 Fallopia multiflora Species 0.000 description 5
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 5
- 231100000360 alopecia Toxicity 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000003797 telogen phase Effects 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 239000003495 polar organic solvent Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000001840 Dandruff Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 3
- 239000004909 Moisturizer Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 230000020411 cell activation Effects 0.000 description 3
- 210000001339 epidermal cell Anatomy 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000031774 hair cycle Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229960003632 minoxidil Drugs 0.000 description 3
- 230000001333 moisturizer Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 description 2
- 101710099518 Dickkopf-related protein 1 Proteins 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229960001456 adenosine triphosphate Drugs 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 1
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 1
- JVKRKMWZYMKVTQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JVKRKMWZYMKVTQ-UHFFFAOYSA-N 0.000 description 1
- ZIMGGGWCDYVHOY-UHFFFAOYSA-N 3-hydroxy-2-imino-6-(1-piperidinyl)-4-pyrimidinamine Chemical compound N=C1N(O)C(N)=CC(N2CCCCC2)=N1 ZIMGGGWCDYVHOY-UHFFFAOYSA-N 0.000 description 1
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 description 1
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000016362 Catenins Human genes 0.000 description 1
- 108010067316 Catenins Proteins 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 101150021185 FGF gene Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000555676 Malassezia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- XJLXINKUBYWONI-NNYOXOHSSA-O NADP(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-O 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 244000292697 Polygonum aviculare Species 0.000 description 1
- 235000006386 Polygonum aviculare Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 229930003571 Vitamin B5 Natural products 0.000 description 1
- 102000044880 Wnt3A Human genes 0.000 description 1
- 108700013515 Wnt3A Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000006567 cellular energy metabolism Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 230000003721 exogen phase Effects 0.000 description 1
- 230000006355 external stress Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 230000009583 hair follicle growth Effects 0.000 description 1
- 230000003661 hair follicle regeneration Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 230000005722 itchiness Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000002488 outer root sheath cell Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 231100000075 skin burn Toxicity 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000004037 social stress Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- OWGHQYPQNSZTFQ-UHFFFAOYSA-M triethyl(octadecyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](CC)(CC)CC OWGHQYPQNSZTFQ-UHFFFAOYSA-M 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 235000021470 vitamin B5 (pantothenic acid) Nutrition 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4933—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having sulfur as an exocyclic substituent, e.g. pyridinethione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
본 개시는 모발 성장 촉진을 유도하는 성분을 함유하는 탈모 방지 및 발모 촉진용 조성물에 관한 것이다. 본 개시의 탈모 방지 및 발모 촉진용 조성물은 특정한 유효성분들 간의 조합을 통해 모유두 세포의 활성, 모유두 세포의 미토콘드리아 활성, 및 Wnt/β-카테닌 신호전달계의 활성을 촉진시켜 탈모 방지 및 발모 촉진 효과에 현저한 시너지 효과를 일으킨다.The present disclosure relates to a composition for preventing hair loss and promoting hair growth containing an ingredient that promotes hair growth. The composition for preventing hair loss and promoting hair growth of the present disclosure promotes the activity of dermal papilla cells, the mitochondrial activity of dermal papilla cells, and the activity of the Wnt/β-catenin signaling system through a combination of specific active ingredients, thereby exhibiting significant anti-hair loss and hair growth promoting effects. It creates a synergistic effect.
Description
본 발명은 탈모 방지 및 발모 촉진용 조성물에 관한 것이다.The present invention relates to a composition for preventing hair loss and promoting hair growth.
시대가 변하면서 미용에 대한 관심이 날로 높아가는 과정에 모발은 중요한 한 부분을 차지하고 있다. 모발은 피부 표면에서 생산된 가늘고 각질화된 구조다. 이것은 외부충격에 대한 쿠션 역할과 더불어 직사광선, 한랭, 마찰, 위험 등 외부 자극으로부터 인체를 보호하고 신체에 유해한 비소, 수은, 아연 등의 중금속이 체 외로 배출되는 기능을 하며 현대에 와서는 장식의 미용 측면도 강조되고 있다. 그 러나 식생활 변화나 내외적 스트레스 증가를 비롯하여 여러 원인에 의해 탈모를 호 소하는 사람들이 늘어나고 있다. 탈모는 유전적 요인이 가장 주요한 원인으로 작용 한다고 알려져 있지만 앞서 말한 바와 같이 사회적 스트레스의 증가, 환경오염, 잦 은 파마와 염색, 및 잘못된 두피 관리들도 탈모의 원인으로 대두되고 있다.As times change, hair plays an important part in the growing interest in beauty. Hair is a thin, keratinized structure produced on the surface of the skin. In addition to acting as a cushion against external shock, it protects the human body from external stimuli such as direct sunlight, cold, friction, and danger, and has the function of excreting heavy metals such as arsenic, mercury, and zinc, which are harmful to the body, out of the body. In modern times, it is used as a decorative beauty. Aspects are also emphasized. However, the number of people complaining of hair loss due to various causes, including changes in diet or increased internal and external stress, is increasing. It is known that genetic factors are the main cause of hair loss, but as mentioned above, increased social stress, environmental pollution, frequent perms and dyeing, and incorrect scalp management are also emerging as causes of hair loss.
사람의 모발은 약 10만-15만 개 정도이며, 각각의 모발은 서로 다른 성장주 기를 가진다. 발생 초기 모낭(hair follicle)의 형성은 베타-카테닌(β-catenin)의 작용에 의해 기저층 표피세포에 의해 플라코드(placode)가 형성된다(Sarah E. Miller, 2002). 형성된 플라코드로부터 신호를 받은 진피 섬유아세포가 피부 응축체(dermal condensate)를 형성한다. 동시에 플라코드는 진피 방향으로 성장, 함입하여 피부 응축체와 합쳐 일차 모발 배종(primary hair germ)을 형성한다. 모발 배종을 형성한 표피 세포는 발생하는 진피방향으로 길게 성장하고, 다층으로 이루 어진 긴 기둥형태의 구조물인 헤어 페그(hair peg)를 형성하는 동시에 피부 응축체 는 구형의 모유두(dermal papilla)로 형성된다. 헤어 페그의 끝쪽은 점점 두꺼워져 모구(hair bulb)가 형성되는데 모구는 모유두를 감싼 형태가 되어 모낭이 완성되고 모낭 내부의 표피세포가 분화하여 모발이 생성된다.There are approximately 100,000 to 150,000 human hairs, and each hair has a different growth cycle. In the early stages of hair follicle formation, a placode is formed by basal layer epidermal cells through the action of β-catenin (Sarah E. Miller, 2002). Dermal fibroblasts that receive signals from the formed placode form dermal condensates. At the same time, the placode grows and invaginates toward the dermis and merges with skin condensates to form primary hair germ. The epidermal cells that form the hair germ grow long in the direction of the developing dermis, forming hair pegs, which are long column-shaped structures made of multiple layers, while skin condensates form spherical dermal papilla. do. The end of the hair peg gradually becomes thicker to form a hair bulb. The hair bulb wraps around the dermal papilla to form a hair follicle, and the epidermal cells inside the hair follicle differentiate to produce hair.
처음 생성된 모발은 성장기 시기를 거쳐 퇴화기, 휴지기로 들어가며, 이후 모발이 탈락된 후 다시 성장기로 들어가는 주기를 돈다. 모발 성장 주기는 3단계로 구성되는데, 모발이 가장 활발하게 성장하는 성장기(anagen stage), 모발의 퇴화가 시작되는 퇴화기(catagen stage), 및 모발의 성장이 멈추거나 휴식에 접어드는 휴지기(telogen stage)로 분류된다.The hair that is first created goes through the growth phase, then into the involution phase and then into the resting phase, and then the hair falls out and goes back into the growth phase again. The hair growth cycle consists of three stages: the anagen stage, when hair grows most actively, the catagen stage, when hair begins to deteriorate, and the telogen stage, when hair growth stops or enters rest. ) is classified as.
이러한 모발의 성장 주기를 조절하는데 있어서, 모낭을 구성하는 모유두 세포와 모낭 줄기세포를 포함한 외모근초세포(outer root sheath cell)의 활성, 및 이들 세포에서 생산되는 다양한 사이토카인 및 성장인자가 중요한 역할을 한다고 알려져 있다. 예를 들어 DKK-1(Dickkopf-1)은 모낭성장 저해와 사멸에 중요한 역할을 한다. 한편, 주기적인 모발 성장을 위해서는 모낭의 재생과 줄기세포의 활성화가 이루어져야 하며, 이는 Wnt/β-카테닌의 생성 및 활성화에 의해 이루어지는 것으로 알려져 있다. 이외에도 VEGF, IGF-1, FGF등의 성장인자는 모발의 성장기를 촉진시키는 것으로 알려져 있고, TGFb-1, EGF 등은 모낭의 퇴행기를 유도하는 성장인자로 알려져 있다.In regulating this hair growth cycle, the activity of outer root sheath cells, including dermal papilla cells and hair follicle stem cells that make up hair follicles, and various cytokines and growth factors produced by these cells play an important role. It is known that it does. For example, DKK-1 (Dickkopf-1) plays an important role in hair follicle growth inhibition and death. Meanwhile, for periodic hair growth, hair follicle regeneration and stem cell activation must occur, and this is known to be achieved through the production and activation of Wnt/β-catenin. In addition, growth factors such as VEGF, IGF-1, and FGF are known to promote the growth phase of hair, and TGFb-1 and EGF are known to be growth factors that induce the catagen phase of hair follicles.
일반적으로 탈모증이라 함은 이러한 주기 중에서 성장기의 모발 비율이 짧아 지고 퇴행기 또는 휴지기의 모발이 많아져 비정상적으로 모발이 탈락하는 숫자가 많아지는 것을 일컫는다. 탈모는 정상적인 현상이나 정상인 사람이 성장기 상태의 모발이 많은데 비해, 보통 탈모증인 사람은 휴지기 상태의 모발이 많아 눈으로 보이는 탈모 현상이 나타내게 된다. 탈모증을 나타내는 사람들의 특징은 모 발의 소형화에 있다. 탈모가 진행될수록 성장기의 기간이 짧아지고 퇴행기, 휴지기 로의 이행이 촉진되며 뒤이은 모유두의 부피가 작아져 모낭은 점점 소형화된다. 따 라서 탈모의 치료를 위해서는 휴지기 상태의 모낭이 성장기로 빨리 이행될 수 있도록 하고, 짧아진 성장기를 늘려주는 것이 중요하다. In general, alopecia refers to a condition in which the proportion of hair in the growth phase becomes shorter and the number of hair in the catagen or telogen phase increases during this cycle, resulting in an abnormal increase in the number of hair shedding. Hair loss is a normal phenomenon, but while normal people have a lot of hair in the growth phase, people with alopecia usually have a lot of hair in the telogen phase, resulting in visible hair loss. A characteristic feature of people with alopecia is miniaturization of hair. As hair loss progresses, the growth period becomes shorter, the transition to the catagen and telogen stages is accelerated, and the subsequent volume of the dermal papilla decreases, causing the hair follicles to become increasingly smaller. Therefore, in order to treat hair loss, it is important to allow hair follicles in the resting state to quickly transition to the growth phase and to lengthen the shortened growth phase.
앞서 언급했듯이 탈모의 원인으로는 남성호르몬 작용, 피지 분비 과다, 혈액 순환 불량, 과산화물이나 세균 등에 의한 두피 기능 저하, 유전적 요인, 노화, 스 트레스 등이 논의되어 왔다. 그러나 현재까지 탈모에 관한 명확한 원인은 밝혀져 있지 않은 상태이며, 매우 복잡한 작용이 얽혀 있는 것으로 알려져 있다.As mentioned earlier, the causes of hair loss have been discussed as the effects of male hormones, excessive sebum secretion, poor blood circulation, decreased scalp function due to peroxides or bacteria, genetic factors, aging, and stress. However, to date, the clear cause of hair loss has not been revealed, and it is known to be a very complex process.
이처럼 다양하고 복잡한 탈모 원인에 대하여, 현재까지 알려진 탈모 방지 제 품에는 유효성분으로 혈행 촉진, 모근 기능 강화, 두피 보습 효과, 비듬 방지 효 과, 항산화 효과, 모발성장기 연장 효과, 남성호르몬 작용 억제 등을 목적으로 하 는 성분 등이 포함되어 있으나, 효과 면에서 뚜렷한 효과를 지닌 것은 아직까지 없는 상태이고 부작용의 문제가 제기되기도 한다.In response to these diverse and complex causes of hair loss, hair loss prevention products known to date include active ingredients that promote blood circulation, strengthen hair root function, scalp moisturizing effect, anti-dandruff effect, antioxidant effect, hair growth extension effect, and male hormone effect inhibition. Although it contains the intended ingredients, there is still no one with a clear effect in terms of effectiveness, and the problem of side effects is sometimes raised.
한편, 아데노신은 세포에서 만들어지는 아미노산의 구성물로 세포 에너지 대사의 주성분이다. 아데노신은 유전자인 DNA를 구성하고 있는 요소 중 하나로 아데닌이라는 염기와 리보스라는 당이 결합된 화합물이다. 아데노신은 당에 세개의 인산이 결합하면 세포내 에너지의 주근원인 ATP(adenosine 5'-triphosphate)가 된다. 이에 따라 아데노신은 신체를 구성하면서 모든 대사가 원활하게 진행되는데 결정적인 역할을 하는 중요한 요소로 알려져 있다. 아데노신은 세포 내 성분이기 때문에 피부 침투시 안정성과 지속력이 뛰어나며 진피층에서 DNA와 단백질 합성을 촉진함으로써 피부 주름 개선에 상승 작용을 한다.Meanwhile, adenosine is an amino acid made in cells and is a main component of cellular energy metabolism. Adenosine is one of the elements that make up DNA, a gene, and is a compound made up of a base called adenine and a sugar called ribose. When three phosphates combine with a sugar, adenosine becomes ATP (adenosine 5'-triphosphate), the main source of intracellular energy. Accordingly, adenosine is known to be an important element that plays a decisive role in the smooth progress of all metabolism in the body. Because adenosine is an intracellular component, it has excellent stability and durability when penetrating the skin, and has a synergistic effect in improving skin wrinkles by promoting DNA and protein synthesis in the dermal layer.
또한, 니아신아미드는 비타민 B 복합체의 일종으로 식물계에서는 니코틴산과 공존하여 광범위하게 분포하고 있으며, 동물계 생체 내에서 산화환원조효소인 NAD 또는 NADP의 성분으로 존재한다. 니아신아미드는 피리딘-3-카르복실산이라고도 알려진 비타민 B3의 생리활성 아미드이며, 이는 항염증성 원료 또는 항산화제로서의 역할도 하는 것으로 알려져 있다. 니아신아미드는 멜라노좀의 이동을 저해하여 합성된 멜라닌이 케라티노사이트로 이동하는 것을 저해고, 이에 따라 피부 색소 침착을 감소시켜 미백 작용을 상승시킨다. 또한, 니아신아미드는 콜라겐 합성 및 세포간 지질의 합성을 증가시켜 피부 보습 등에 유리한 작용을 한다.In addition, niacinamide is a type of vitamin B complex and is widely distributed in the plant world, coexisting with nicotinic acid. In the animal world, it exists as a component of NAD or NADP, a redox coenzyme. Niacinamide is a bioactive amide of vitamin B3, also known as pyridine-3-carboxylic acid, and is known to act as an anti-inflammatory ingredient or antioxidant. Niacinamide inhibits the movement of melanosomes, thereby inhibiting the movement of synthesized melanin to keratinocytes, thereby reducing skin pigmentation and increasing whitening effect. In addition, niacinamide has a beneficial effect on skin moisturization by increasing collagen synthesis and intercellular lipid synthesis.
또한, D-판테놀(덱스판테놀)은 비타민 B5(Pantothenic acid)의 알콜 형태로 프로비타민 B5라고 할 수 있다. D-판테놀은 피부에 흡수되면서 비타민 B5로 바로 전환되어 사용된다. D-판테놀은 피부 보습제, 주름개선제 등의 성분으로 화장품, 생활용품에서 많이 사용되고, 또한 상처치유, 피부화상, 간지러움 개선 등의 연고제로도 사용된다. 또한, D-판테놀은 침투성이 있는 보습제로 알려져 있으며, 피부와 모발의 컨디셔닝 효과를 주고, 손상 모발의 회복을 증가시켜 주는 효능이 알려져 있다.Additionally, D-panthenol (dexpanthenol) is an alcoholic form of vitamin B5 (Pantothenic acid) and can be called provitamin B5. D-Panthenol is absorbed into the skin and converted directly into vitamin B5. D-Panthenol is widely used in cosmetics and household goods as an ingredient in skin moisturizers and wrinkle improvers, and is also used as an ointment for wound healing, skin burns, and itchiness improvement. In addition, D-panthenol is known as a penetrating moisturizer, and is known to have a conditioning effect on skin and hair and increase recovery of damaged hair.
또한, 하수오는 마디풀과에 속하는 다년생 초로 덩굴성 약용식물이며, 이의 학명은 Pleuropterus multiflorus, Polygonum multiflorum, Fagopyrum multiflorum, Reynoutria multiflora, 또는 Fallopia multiflora로 다양하다. 하수오 추출물은 강장제, 강정제, 통경제, 양혈제, 또는 진해제 등으로 활용되며, 감기, 토혈, 신경쇠약, 또는 관절염 치료 등에 쓰이는 것으로 알려져 있다.In addition, Hasuo is a perennial herbaceous vine medicinal plant belonging to the knotweed family, and its scientific names are Pleuropterus multiflorus , Polygonum multiflorum , Fagopyrum multiflorum , Reynoutria multiflora , or Fallopia multiflora . The extract of Haushuo is used as a tonic, tonic, tonic, blood purifier, or antitussive, and is known to be used to treat colds, hematemesis, nervous breakdown, or arthritis.
또한, 어성초(Houttuynia cordata)는 삼백초과의 여러해살이풀로서 약모밀, 중약초, 즙채 또는 십약으로 알려진 약초이다. 어성초는 다양한 정유 성분을 함유하고 있어 고기 비린 내와 같은 독특한 냄새를 내기 때문에 어성초라고 불린다. 어성초는 주로 5~7월에 꽃이 피며, 민간에서 임질, 장염, 요로감염증, 폐렴, 또는 기관지염 등에 쓰이는 약초이다.In addition, Houttuynia cordata is a perennial herb of the Trifoliaceae family and is a medicinal herb known as medicinal herb, Chinese herb, japchae, or ten yak. Houttuynia cordata is called Houttuynia cordata because it contains a variety of essential oils and produces a unique smell like fishy meat. Houttuynia cordata mainly blooms from May to July, and is a medicinal herb used in the private sector for gonorrhea, enteritis, urinary tract infection, pneumonia, or bronchitis.
또한, 징크피리치온(zinc pyrithione)은 항균 작용이 있어 두피와 피부에서 미생물의 번식을 막는다. 특히 징크피리치온은 말라세지아(malassezia)와 다른 진균류들에 대한 번식 억제 작용이 있어, 두피의 지루성 피부염 및 비듬 생성을 방지하는 역할을 한다.Additionally, zinc pyrithione has an antibacterial effect and prevents the growth of microorganisms on the scalp and skin. In particular, zinc pyrithione has an inhibitory effect on the growth of malassezia and other fungi, preventing seborrheic dermatitis and dandruff on the scalp.
또한, 살리실산은 아스피린의 주성분이며 항염증제, 진통제 또는 해열제로 널리 사용되어 왔다. 살리실산은 피부의 각질 제거 및 각질 연화 작용을 한다. 살리실산은 주로 클렌징폼과 같은 화장품에 첨가되어 각질을 연화 및 박리시켜 모공을 부드럽게 한다. 이를 통해, 살리실산은 모공 속 피지의 배출을 돕고 피부를 깨끗하게 유지시킬 수 있다. 또한, 살리실산은 항균 및 항염 작용을 나타내어, 두피 또는 피부 미생물의 번식을 억제하여 피부 및 두피를 개선하거나 비듬을 방지할 수 있다.In addition, salicylic acid is the main component of aspirin and has been widely used as an anti-inflammatory, analgesic, or antipyretic agent. Salicylic acid has the effect of exfoliating and softening the skin. Salicylic acid is mainly added to cosmetics such as cleansing foam to soften pores by softening and exfoliating dead skin cells. Through this, salicylic acid can help excrete sebum from pores and keep the skin clean. In addition, salicylic acid exhibits antibacterial and anti-inflammatory effects and can improve the skin and scalp or prevent dandruff by inhibiting the growth of scalp or skin microorganisms.
한편, 현재 미국식품의약품안전청(FDA)에서 승인을 받은 도포제의 탈모 치료제는 미녹시딜(2,4-diamino-6-piperidinopyrimidine-3-oxide)이 유일하지만 32주에서 48주 사용시 그 효과가 각각 38% 및 13%로 만족스럽지 못한 실정이며 앞머리에는 효과가 떨어진다는 단점이 있다.Meanwhile, the only topical hair loss treatment currently approved by the U.S. Food and Drug Administration (FDA) is minoxidil (2,4-diamino-6-piperidinopyrimidine-3-oxide), but its effectiveness is 38% when used for 32 to 48 weeks. and 13%, which is unsatisfactory, and has the disadvantage of being less effective on bangs.
이와 같이, 탈모 방지 또는 발모 촉진에 효과가 우수한 조성물의 개발이 필요한 실정인데, 상기 아데노신, D-판테놀, 니아신아미드, 하수오 추출물, 어성초 추출물, 징크피리치온 및 살리실산 등을 조합할 때 탈모 방지 또는 발모 촉진에 어떠한 효과가 나타나는지에 대해서는 연구가 부족한 실정이다.As such, there is a need to develop a composition that is effective in preventing hair loss or promoting hair growth. When adenosine, D-panthenol, niacinamide, Houttuynia cordata extract, Houttuynia cordata extract, zinc pyrithione, and salicylic acid are combined, hair loss prevention or There is a lack of research on what effect it has on hair growth promotion.
본 개시가 해결하고자 하는 과제는 우수한 탈모 방지 및/또는 발모 촉진 효과를 갖는 탈모 방지 또는 발모 촉진용 조성물을 제공하는 것이다.The problem to be solved by the present disclosure is to provide a composition for preventing hair loss or promoting hair growth that has excellent hair loss preventing and/or hair growth promoting effects.
또한, 본 개시가 해결하고자 하는 과제는 상기 탈모 방지 또는 발모 촉진용 조성물을 포함하는 헤어 또는 두피용 제품을 제공하는 것이다.In addition, the problem to be solved by the present disclosure is to provide a hair or scalp product containing the composition for preventing hair loss or promoting hair growth.
본 발명자들은 종래의 탈모 치료제의 부작용 및 사용상의 주의사항 등의 문제점을 개선하고 탈모 방지/양모제의 발모 촉진 효과가 미약한 등의 단점 없이, 인체에 대해 안전하면서도 탈모 방지 및 발모 촉진에 효과적으로 작용할 수 있는 조성물을 개발하고자 예의 노력하였다. 그 결과, 본 발명자들은 아데노신, D-판테놀 및 니아신아미드의 혼합물에 특정한 유효성분을 추가로 조합하는 경우, 탈모 방지 및 발모 촉진에 현저한 시너지 효과가 발생함을 발견하였다.The present inventors have improved problems such as side effects and precautions for use of conventional hair loss treatments, and have developed a method that is safe for the human body and can effectively prevent hair loss and promote hair growth without disadvantages such as the weak hair growth promotion effect of hair loss prevention/hair growth agents. We made diligent efforts to develop a composition that contains As a result, the present inventors discovered that when specific active ingredients are additionally combined with a mixture of adenosine, D-panthenol, and niacinamide, a significant synergistic effect occurs in preventing hair loss and promoting hair growth.
구체적으로, 본 발명자들은 인비트로(in-vitro) 실험을 통해 아데노신, D-판테놀 및 니아신아미드의 혼합물에 하수오 추출물, 어성초 추출물, 징크피리치온 및 살리실산으로 이루어진 군에서 선택된 어느 하나 이상을 추가로 조합하는 경우, 모유두세포 활성 증진 효과(실험예 1), 모유두 세포 미토콘드리아 활성 촉진 효과(실험예 2), 모유두 세포 활성 신호(Wnt/β-catenin) 촉진 효과(실험예 3)에 현저한 시너지 효과가 발생함을 확인하였다. 또한, 본 발명자들은 상기 조합을 포함하는 탈모 방지 또는 발모 촉진용 조성물을 탈모증 환자에게 처리할 때, 단위 면적당 모발 개수 및 평균 모발 두께가 현저하게 개선되어 탈모증의 치료에 현저하게 우수한 효과가 있음을 확인하였다(실험예 4, 5).Specifically, through in-vitro experiments, the present inventors added at least one selected from the group consisting of Houttuynia cordata extract, Houttuynia cordata extract, zinc pyrithione, and salicylic acid to a mixture of adenosine, D-panthenol, and niacinamide. When combined, there is a significant synergy effect in the effect of promoting hair papilla cell activity (Experimental Example 1), the effect of promoting mitochondrial activity of hair papilla cells (Experimental Example 2), and the effect of promoting dermal papilla cell activity signaling (Wnt/β-catenin) (Experimental Example 3). It was confirmed that this occurred. In addition, the present inventors confirmed that when treating alopecia patients with a composition for preventing hair loss or promoting hair growth containing the above combination, the number of hairs per unit area and the average hair thickness were significantly improved, resulting in a significantly excellent effect in the treatment of alopecia. (Experimental Examples 4 and 5).
본 개시는 아데노신, D-판테놀 및 니아신아미드의 혼합물; 및 하수오 추출물, 어성초 추출물, 징크피리치온 및 살리실산으로 이루어진 군에서 선택된 어느 하나 이상을 유효성분으로 포함하는 탈모 방지 또는 발모 촉진용 조성물을 제공한다. 본 개시의 일 양태에서, 본 개시는 아데노신, D-판테놀 및 니아신아미드의 혼합물; 하수오 추출물, 어성초 추출물 또는 이들 모두; 및 징크피리치온, 살리실산 또는 이들 모두를 유효성분으로 포함하는 탈모 방지 또는 발모 촉진용 조성물을 제공한다. 상기 탈모 방지 또는 발모 촉진용 조성물은 상기 유효성분들 간의 조합에 의해 탈모 방지 또는 발모 촉진에 현저한 시너지 효과가 발생한다.The present disclosure provides a mixture of adenosine, D-panthenol, and niacinamide; And it provides a composition for preventing hair loss or promoting hair growth, comprising as an active ingredient at least one selected from the group consisting of Houttuynia cordata extract, Houttuynia cordata extract, zinc pyrithione, and salicylic acid. In one aspect of the disclosure, the disclosure provides a mixture of adenosine, D-panthenol, and niacinamide; Houttuynia cordata extract, Houttuynia cordata extract, or both; And it provides a composition for preventing hair loss or promoting hair growth containing zinc pyrithione, salicylic acid, or both as active ingredients. The composition for preventing hair loss or promoting hair growth produces a significant synergy effect in preventing hair loss or promoting hair growth by combining the active ingredients.
본 개시의 일 양태에서, 상기 하수오 추출물 또는 어성초 추출물은 당업계에 공지된 방법에 의해 추출될 수 있으며, 그 방법은 특별히 한정되지 않으며, 또는 시판되고 있는 추출물을 이용할 수 있다. 다른 양태에서, 상기 하수오 추출물 또는 어성초 추출물은 하수오 또는 어성초를 물 및/또는 유기용매로 추출하여 수득한 추출물을 사용할 수 있으며, 상기 유기용매는 극성 유기용매, 비극성 유기용매 또는 이들의 혼합 용매일 수 있다. 상기 극성 유기용매는 탄소수 1 내지 5의 저급 알코올, 에틸아세테이트 또는 아세톤 등일 수 있으며, 비극성 유기용매는 에테르, 클로로포름, 벤젠, 핵산 또는 디클로로메탄 등일 수 있다. 예를 들어, 상기 탄소수 1 내지 5의 저급 알코올은 메탄올, 에탄올, 프로판올, 부탄올 또는 이소프로판올 등일 수 있다.In one aspect of the present disclosure, the Houttuynia cordata extract or Houttuynia cordata extract can be extracted by a method known in the art, and the method is not particularly limited, or a commercially available extract can be used. In another embodiment, the extract of Houttuynia cordata or Houttuynia cordata extract may be an extract obtained by extracting Houttuynia cordata or Houttuynia cordata with water and/or an organic solvent, and the organic solvent may be a polar organic solvent, a non-polar organic solvent, or a mixed solvent thereof. there is. The polar organic solvent may be a lower alcohol having 1 to 5 carbon atoms, ethyl acetate, or acetone, and the non-polar organic solvent may be ether, chloroform, benzene, nucleic acid, or dichloromethane. For example, the lower alcohol having 1 to 5 carbon atoms may be methanol, ethanol, propanol, butanol, or isopropanol.
본 개시의 일 양태에서, 상기 하수오 추출물 또는 어성초 추출물은 전술한 추출용매를 이용하여 추출된 1차 추출물을 극성이 다른 추출용매를 이용하여 분획한 분획물을 포함할 수 있다. 예를 들어, 하수오 추출물 또는 어성초 추출물은 탄소수 1 내지 5의 알코올로 추출 한 후, 에테르, 벤젠, 헥산 등의 극성이 다른 용매로 다시 분획한 분획물일 수 있다. 상기 분획 시 용매는 2종 이상 사용할 수 있으며, 용매의 극성에 따라 순차적으로 사용하거나 혼합하여 사용하여, 각 용매 추출물을 제조할 수 있다.In one aspect of the present disclosure, the Houttuynia cordata extract or Houttuynia cordata extract may include a fraction obtained by fractionating the primary extract extracted using the above-described extraction solvent using an extraction solvent of different polarity. For example, the extract of Houttuynia cordata or Houttuynia cordata extract may be a fraction extracted with an alcohol having 1 to 5 carbon atoms and then fractionated again with a solvent of different polarity such as ether, benzene, or hexane. Two or more types of solvents can be used during the fractionation, and extracts for each solvent can be prepared by using them sequentially or by mixing them depending on the polarity of the solvents.
본 개시의 일 양태에서, 상기 제조된 추출물 또는 상기 분획과정을 수행하여 수득한 분획물에 대해 여과하거나 농축 또는 건조과정을 수행하여 용매를 제거할 수 있으며, 상기 여과, 농축 및 건조를 모두 수행할 수 있다. 구체적으로 상기 여과는 여과지를 이용하거나 감압여과기를 이용할 수 있고, 농축은 감압 농축기 등을 이용하여 감압 농축할 수 있으며, 건조는 동결건조법을 수행할 수 있다. 또한, 상기 제조된 추출물 또는 상기 분획과정을 수행하여 수득한 분획물에 대해 실리카겔 컬럼 크로마토그래피, 박층 크로마토그래피 또는 고성능 액체 크로마토그래피 등의 다양한 크로마토그래피를 이용하여 정제함으로써 추가로 정제된 분획을 얻을 수 있다.In one aspect of the present disclosure, the prepared extract or the fraction obtained by performing the fractionation process may be filtered, concentrated, or dried to remove the solvent, and the filtration, concentration, and drying may all be performed. there is. Specifically, the filtration can be performed using filter paper or a vacuum filter, the concentration can be performed under reduced pressure using a vacuum concentrator, etc., and the drying can be performed using a freeze-drying method. In addition, the prepared extract or the fraction obtained by performing the above fractionation process is purified using various chromatographies such as silica gel column chromatography, thin layer chromatography, or high-performance liquid chromatography to obtain an additional purified fraction. .
본 개시의 일 양태에서, 본 개시의 탈모 방지 또는 발모 촉진용 조성물에 포함되는 아데노신, D-판테놀 및 니아신아미드의 혼합물; 및 하수오 추출물, 어성초 추출물, 징크피리치온 및 살리실산으로 이루어진 군에서 선택된 어느 하나 이상을 포함하는 유효성분의 함량은 조성물 총 중량 대비 0.0001 내지 10 중량%, 바람직하게 0.001 내지 7 중량%, 더욱 바람직하게 0.01 내지 5 중량%일 수 있다. 상기 유효성분들의 총 함량이 조성물 총 중량 대비 0.0001 중량% 미만일 경우에는 발모 유도 촉진 효과가 미미하고, 10 중량% 초과일 경우에는 제형의 안정성이 떨어져 바람직하지 않다. 본 개시에서는 유효성분이 상기 함량 범위일 때 탈모 방지 및 발모 촉진 효능이 현저하게 우수함을 실험을 통해 확인하였다.In one aspect of the present disclosure, a mixture of adenosine, D-panthenol, and niacinamide included in the composition for preventing hair loss or promoting hair growth of the present disclosure; And the content of the active ingredient containing any one or more selected from the group consisting of Houttuynia cordata extract, Houttuynia cordata extract, zinc pyrithione, and salicylic acid is 0.0001 to 10% by weight, preferably 0.001 to 7% by weight, more preferably 0.001 to 7% by weight, based on the total weight of the composition. It may be 0.01 to 5% by weight. If the total content of the active ingredients is less than 0.0001% by weight based on the total weight of the composition, the hair growth inducing promoting effect is minimal, and if it is more than 10% by weight, the stability of the formulation is poor and thus undesirable. In the present disclosure, it was confirmed through experiments that the efficacy of preventing hair loss and promoting hair growth was significantly superior when the active ingredient was in the above content range.
본 개시의 일 양태에서, 본 개시의 탈모 방지 또는 발모 촉진용 조성물에 유효성분으로 포함되는 아데노신, D-판테놀 및 니아신아미드의 혼합물의 함량은 조성물 총 중량 대비 0.0001 내지 10 중량%, 바람직하게 0.001 내지 10 중량%일 수 있다. 상기 아데노신, D-판테놀 및 니아신아미드의 혼합물의 함량이 조성물 총 중량 대비 0.0001 중량% 미만일 경우에는 발모 유도 촉진 효과가 미미하고, 10 중량% 초과일 경우에는 제형의 안정성이 떨어져 바람직하지 않다.In one aspect of the present disclosure, the content of the mixture of adenosine, D-panthenol, and niacinamide included as active ingredients in the composition for preventing hair loss or promoting hair growth of the present disclosure is 0.0001 to 10% by weight, preferably 0.001 to 0.001% by weight, based on the total weight of the composition. It may be 10% by weight. If the content of the mixture of adenosine, D-panthenol and niacinamide is less than 0.0001% by weight based on the total weight of the composition, the effect of promoting hair growth induction is minimal, and if it is more than 10% by weight, the stability of the formulation is poor and thus undesirable.
본 개시의 일 양태에서, 본 개시의 탈모 방지 또는 발모 촉진용 조성물에 추가적인 유효성분으로 포함되는 하수오 추출물, 어성초 추출물, 징크피리치온 및 살리실산으로 이루어진 군에서 선택된 어느 하나 이상의 함량은 조성물 총 중량 대비 0.00001 내지 10 중량%, 바람직하게 0.0001 내지 5 중량%일 수 있다. 상기 하수오 추출물, 어성초 추출물, 징크피리치온 및 살리실산으로 이루어진 군에서 선택된 어느 하나 이상의 함량이 조성물 총 중량 대비 0.00001 중량% 미만일 경우에는 발모 촉진에 시너지 효과가 미미하고, 10 중량% 초과일 경우에는 제형의 안정성이 떨어져 바람직하지 않다.In one aspect of the present disclosure, the content of one or more selected from the group consisting of Houttuynia cordata extract, Houttuynia cordata extract, zinc pyrithione, and salicylic acid included as an additional active ingredient in the composition for preventing hair loss or promoting hair growth of the present disclosure is relative to the total weight of the composition. It may be 0.00001 to 10% by weight, preferably 0.0001 to 5% by weight. If the content of any one or more selected from the group consisting of Houttuynia cordata extract, Houttuynia cordata extract, zinc pyrithione, and salicylic acid is less than 0.00001% by weight of the total weight of the composition, the synergistic effect in promoting hair growth is minimal, and if it is more than 10% by weight, the formulation It is undesirable due to poor stability.
본 개시의 일 양태에서, 상기 아데노신, D-판테놀 및 니아신아미드의 혼합물의 중량비는 1:0.3~5:0.2~8, 바람직하게 1:0.5~4:0.3~6(아데노신:D-판테놀:니아신아미드)일 수 있다. 상기 아데노신, D-판테놀 및 니아신아미드의 혼합물이 상기 특정한 중량비로 조합될 경우, 탈모 방지 및 발모 촉진 효과가 탁월하다.In one aspect of the present disclosure, the weight ratio of the mixture of adenosine, D-panthenol and niacinamide is 1:0.3 to 5:0.2 to 8, preferably 1:0.5 to 4:0.3 to 6 (adenosine:D-panthenol:niacin amide). When the mixture of adenosine, D-panthenol, and niacinamide is combined at the specific weight ratio, the effect of preventing hair loss and promoting hair growth is excellent.
본 개시의 일 양태에 있어서, 본 개시의 탈모 방지 또는 발모 촉진용 조성물은 의약 조성물, 의약외품용 조성물, 화장료 조성물 또는 건강기능식품 조성물로 사용될 수 있다. 본 개시의 조성물은 통상적으로 피부에 적용시킬 수 있는 어떠한 형태로도 제형화 될 수 있으나, 바람직하게 피부 외용제의 형태로 제형화될 수 있다. 본 개시의 조 성물은 예를 들어 액상, 크림상, 페이스트상, 또는 고체상 등 피부에 적용시킬 수 있는 제형으로 제조될 수 있다.In one aspect of the present disclosure, the composition for preventing hair loss or promoting hair growth of the present disclosure may be used as a pharmaceutical composition, a quasi-drug composition, a cosmetic composition, or a health functional food composition. The composition of the present disclosure can be formulated in any form that can be generally applied to the skin, but is preferably formulated in the form of an external skin preparation. The composition of the present disclosure can be prepared in a formulation that can be applied to the skin, for example, in a liquid, cream, paste, or solid form.
본 개시의 아데노신, D-판테놀 및 니아신아미드의 혼합물; 및 하수오 추출물, 어성초 추출물, 징크피리치온 및 살리실산으로 이루어진 군에서 선택된 어느 하나 이상은 상기 조성물 또는 제형에 탈모 방지제 또는 모발 성장 촉진제로 포함될 수 있다.A mixture of adenosine, D-panthenol, and niacinamide of the present disclosure; And any one or more selected from the group consisting of Houttuynia cordata extract, Houttuynia cordata extract, zinc pyrithione, and salicylic acid may be included in the composition or formulation as an anti-hair loss agent or hair growth promoter.
본 개시의 제형이 액상인 경우에는 담체 성분으로 용매, 용해화제 또는 유탁화제 등이 사용될 수 있고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르 등이 사용될 수 있다.When the formulation of the present disclosure is in a liquid form, solvents, solubilizers, or emulsifying agents may be used as carrier components, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1, 3-Butyl glycol oil, glycerol aliphatic ester, polyethylene glycol, or sorbitan fatty acid ester may be used.
본 개시의 제형이 페이스트, 크림 또는 젤인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 사용될 수 있다.When the formulation of the present disclosure is a paste, cream, or gel, animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, or zinc oxide may be used as the carrier ingredient. there is.
본 개시의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더 등이 이용될 수 있다. 특히 스프레이 제형인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르 등과 같은 추진체를 포함할 수 있다.When the formulation of the present disclosure is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, or polyamide powder may be used as the carrier component. In particular, in the case of a spray formulation, it may additionally contain a propellant such as chlorofluorohydrocarbon, propane/butane, or dimethyl ether.
본 개시의 조성물에는 상기 유효성분 외에 피부에 적용시킬 수 있는 외용제로 통상적으로 이용되는 성분들을 포함할 수 있다. 예를 들어 물, 계면활성제, 보습제, 저급알코올, 킬레이트제, 살균제, 산화방지제, 방부제, 색소 및 향료 등으로 이루어지는 군으로부터 선택되는 하나 이상의 첨가제가 추가로 포함될 수 있다.In addition to the above active ingredients, the composition of the present disclosure may include ingredients commonly used as external agents that can be applied to the skin. For example, one or more additives selected from the group consisting of water, surfactants, moisturizers, lower alcohols, chelating agents, disinfectants, antioxidants, preservatives, colorants, and fragrances may be additionally included.
또한, 본 개시는 상기 탈모 방지 또는 발모 촉진용 조성물을 포함하는 헤어 또는 두피용 제품을 제공한다. 상기 헤어 또는 두피용 제품은 발모제, 두피클리닉제, 두피스케일링제, 두피마사지제, 두피케어제, 세정제, 샴푸, 토닉, 헤어컨디셔너, 헤어로션, 젤, 팩, 크림, 에센스, 파우더, 스프레이, 오일, 비누, 연고, 헤어스타일링제, 염모제 및 펌제 등으로 이루어진 군으로부터 선택된 어느 하나일 수 있으나, 이에 한정되지 않는다.Additionally, the present disclosure provides a hair or scalp product containing the composition for preventing hair loss or promoting hair growth. The above hair or scalp products include hair growth agents, scalp clinic agents, scalp scaling agents, scalp massage agents, scalp care agents, detergents, shampoos, tonics, hair conditioners, hair lotions, gels, packs, creams, essences, powders, sprays, and oils. , may be any one selected from the group consisting of soap, ointment, hair styling agent, hair dye, perm agent, etc., but is not limited thereto.
본 개시의 일 양태에서, 상기 탈모 방지 또는 발모 촉진용 조성물은 헤어토닉 또는 헤어로션의 제형으로 제조될 수 있다 (제조예 1 내지 3).In one aspect of the present disclosure, the composition for preventing hair loss or promoting hair growth may be prepared in the form of a hair tonic or hair lotion (Preparation Examples 1 to 3).
본 개시의 탈모 방지 또는 발모 촉진용 조성물은 바람직하게 피부에 직접 도포하거나 살포하는 등의 경피 투여 방법으로 사용될 수 있다.The composition for preventing hair loss or promoting hair growth of the present disclosure can preferably be used by a transdermal administration method such as directly applying or spraying to the skin.
또한, 본 개시는 상기 탈모 방지 또는 발모 촉진용 조성물을 포함하는 건강기능식품 조성물을 제공한다. 상기 건강기능식품 조성물은 당업계에서 통상적으로 사용되는 방법에 의하여 제조될 수 있다. 상기 제조시에는 당업계에서 통상적으로 첨가하는 원료 및 성분을 첨가하여 제조할 수 있다. 또한 상기 건강기능식품의 제형 또한 건강기능식품으로 인정되는 제형이면 제한 없이 제조될 수 있다. 본 개시의 건강기능식품은 다양한 형태의 제형으로 제조될 수 있으며, 식품을 원료로 하여 약품의 장기 복용시 발생할 수 있는 부작용 등이 없는 장점이 있고 휴대성이 뛰어나 탈모 방지 또는 발모 촉진 효과를 증진시키기 위한 보조제로 섭취될 수 있다.In addition, the present disclosure provides a health functional food composition containing the composition for preventing hair loss or promoting hair growth. The health functional food composition can be prepared by methods commonly used in the art. In the above manufacturing process, it can be manufactured by adding raw materials and components commonly added in the industry. Additionally, the formulation of the health functional food can also be manufactured without limitation as long as it is a formulation recognized as a health functional food. The health functional food of the present disclosure can be manufactured in a variety of formulations, is made from food, has the advantage of having no side effects that may occur when taking drugs for a long time, and is highly portable, so it can prevent hair loss or promote hair growth. It can be taken as a supplement for:
또한, 본 개시는 아데노신, D-판테놀 및 니아신아미드의 혼합물; 및 하수오 추출물, 어성초 추출물, 징크피리치온 및 살리실산으로 이루어진 군에서 선택된 어느 하나 이상을 유효성분으로 포함하는 탈모 방지 또는 발모 촉진용 조성물을 환자(subject)에게 투여하는 단계를 포함하는 탈모 방지 또는 발모 촉진 방법을 제공한다. 본 개시의 일 양태에서, 상기 탈모 방지 또는 발모 촉진 방법은 상기 탈모 방지 또는 발모 촉진용 조성물을 환자의 두피 또는 모발에 처리하는 단계를 포함할 수 있다.Additionally, the present disclosure provides a mixture of adenosine, D-panthenol, and niacinamide; And hair loss prevention or hair growth comprising the step of administering to a subject a composition for preventing hair loss or promoting hair growth containing as an active ingredient at least one selected from the group consisting of Houttuynia cordata extract, Houttuynia cordata extract, zinc pyrithione, and salicylic acid. Provides methods of promotion. In one aspect of the present disclosure, the method for preventing hair loss or promoting hair growth may include treating the patient's scalp or hair with the composition for preventing hair loss or promoting hair growth.
본 개시에서 사용되는 용어, "투여"는 어떠한 적절한 방법으로 본 개시의 조성물을 도입하는 것을 의미할 수 있다. 본 개시의 조성물의 투여 경로는 목적 조직에 도달할 수 있는 한 어떠한 일반적인 경로를 통하여 투여될 수 있다. 바람직하게는 경피 투여할 수 있으며, 그 중에서도 국소 도포가 가장 바람직하다. 본 개시의 조성물의 적용 횟수는 처방, 필요 또는 원하는 바에 따라 결정될 수 있다.As used in this disclosure, the term “administration” may mean introducing a composition of this disclosure by any suitable method. The administration route of the composition of the present disclosure can be administered through any general route as long as it can reach the target tissue. Preferably, it can be administered transdermally, and topical application is most preferable. The number of applications of the composition of the present disclosure may be determined according to prescription, need, or desire.
본 개시의 탈모 방지 또는 발모 촉진용 조성물의 사용량은 연령, 병변의 정도 등의 개인 차이나 제형에 따라 적절하게 조절될 수 있으며, 통상 1일 1회 내지 수회 적당량을 두피에 도포시켜 1주일 내지 수개월 사용하는 것이 바람직하다. 본 개시의 실험예에서는 탈모 치료용 조성물 1을 1주에 5회씩 6개월 동안 사용하였으며, 그 결과 우수한 모발 성장 촉진 효과가 나타났음을 확인하였다 (실험예 4, 5).The amount of the composition for preventing hair loss or promoting hair growth of the present disclosure can be appropriately adjusted depending on individual differences such as age, degree of lesion, etc., and the formulation. Typically, an appropriate amount is applied to the scalp once or several times a day and used for one week to several months. It is desirable to do so. In the experimental example of the present disclosure, Composition 1 for hair loss treatment was used 5 times a week for 6 months, and as a result, it was confirmed that an excellent hair growth promotion effect was observed (Experimental Examples 4 and 5).
본 개시에 기재된 모든 성분은, 바람직하게는, 한국, 중국, 미국, 유럽, 일본 등의 관련 법규, 규범 (예를 들어, 화장품 안전 기준 등에 관한 규정(한국), 화장품 안전 기술 규범(중국), 식품공전(한국), 식품첨가물공전(한국), 건강기능식품공전(한국)) 등에서 규정한 최대 사용치를 초과하지 않는다. 즉, 바람직하게, 본 개시에 따른 의약 조성물, 의약외품용 조성물, 화장료 조성물 또는 건강기능식품 조성물은 각국의 관련 법규, 규범에서 허용되는 함량 한도로 본 개시에 따른 성분들을 포함한다.All ingredients described in the present disclosure are preferably subject to relevant laws and regulations of Korea, China, the United States, Europe, Japan, etc. (e.g., Regulations on Cosmetic Safety Standards, etc. (Korea), Cosmetic Safety Technical Regulations (China), etc. Do not exceed the maximum usage level specified in the Food Code (Korea), Food Additives Code (Korea), and Health Functional Food Code (Korea). That is, preferably, the pharmaceutical composition, quasi-drug composition, cosmetic composition, or health functional food composition according to the present disclosure contains the ingredients according to the present disclosure within the content limit permitted by the relevant laws and regulations of each country.
본 개시의 탈모 방지 및 발모 촉진용 조성물은 특정한 유효성분들 간의 조합을 통해 모유두 세포의 활성, 모유두 세포의 미토콘드리아 활성, 및 Wnt/β-카테닌 신호전달계의 활성을 촉진시켜 탈모 방지 및 발모 촉진 효과에 현저한 시너지 효과를 일으킨다.The composition for preventing hair loss and promoting hair growth of the present disclosure promotes the activity of dermal papilla cells, the mitochondrial activity of dermal papilla cells, and the activity of the Wnt/β-catenin signaling system through a combination of specific active ingredients, thereby exhibiting significant anti-hair loss and hair growth promoting effects. It creates a synergistic effect.
이하, 본 발명의 이해를 돕기 위하여 실시예 등을 들어 상세하게 설명하기로 한다. 그러나, 본 발명에 따른 실시예들은 여러 가지 다른 형태로 변형될 수 있으며, 본 발명의 범위가 하기 실시예들에 한정되는 것으로 해석되어서는 안 된다. 본 발명의 실시예들은 본 발명이 속한 분야에서 평균적인 지식을 가진 자에게 본 발명을 보다 완전하게 설명하기 위해 제공되는 것이다.Hereinafter, to aid understanding of the present invention, it will be described in detail through examples. However, the embodiments according to the present invention may be modified into various other forms, and the scope of the present invention should not be construed as being limited to the following embodiments. Embodiments of the present invention are provided to more completely explain the present invention to those with average knowledge in the field to which the present invention pertains.
제조예 1: 탈모 치료용 조성물 1 (헤어토닉)Preparation Example 1: Composition 1 for hair loss treatment (hair tonic)
아데노신, D-판테놀, 니아신아미드의 혼합물의 중량비를 달리하여, 하기 표 1에 개시된 처방에 따라 통상의 방법으로 헤어토닉을 제조하였다.A hair tonic was prepared in a conventional manner according to the recipe shown in Table 1 below, by varying the weight ratio of the mixture of adenosine, D-panthenol, and niacinamide.
제조예 2: 탈모 치료용 조성물 2 (헤어토닉)Preparation Example 2: Composition 2 for hair loss treatment (hair tonic)
하기 표 2에 개시된 처방에 따라, 하수오 추출물, 어성초 추출물, 징크피리치온, 또는 살리실산을 각각 1종씩 추가하여, 통상의 방법으로 헤어토닉을 제조하였다.According to the prescription disclosed in Table 2 below, a hair tonic was prepared in a conventional manner by adding one each of Hewlett-Packard extract, Houttuynia cordata extract, zinc pyrithione, or salicylic acid.
제조예 3: 탈모 치료용 조성물 3 (헤어로션)Preparation Example 3: Composition 3 for hair loss treatment (hair lotion)
아데노신, D-판테놀, 니아신아미드의 혼합물에 하수오 추출물, 어성초 추출물, 징크피리치온, 살리실산 중 1종 이상을 하기 표 3에 개시된 처방에 따라 통상의 방법으로 헤어로션을 제조하였다.Hair lotion was prepared in a conventional manner according to the recipe shown in Table 3 below by adding one or more of Houttuynia cordata extract, Houttuynia cordata extract, zinc pyrithione, and salicylic acid to a mixture of adenosine, D-panthenol, and niacinamide.
실험예 1: 모유두 세포 활성 증진 효과Experimental Example 1: Effect of enhancing dermal papilla cell activity
인간 유래 모유두 세포(dermal papilla cells, DPCs)는 프로모셀사에서 구입하였다. 상기 DPCs을 5% 우태아 혈청(FBS; Gibco, NY, USA), 페니실린100 unit/mL 및 스트렙토마이신 100 ㎍/mL이 포함된 DMEM(Hyclone Inc, UT, USA)에서 37℃ 및 5% CO2 조건하에 배양하였다. 배양한 DPCs 3,000 cells/well을 96-well 플레이트에 분주한 뒤, 0.1% 혈청 조건에서 24h 동안 배양하였다. 그 후, 배양한 세포에 무혈청 DMEM에 1:1000으로 희석한 DMSO(vehicle)을 대조군으로, 미녹시딜 2 ㎍/㎖을 양성대조군으로, 아데노신, D-판테놀, 니아신아미드의 혼합물에 하수오 추출물, 어성초 추출물, 징크피리치온, 살리실산 중 1종 이상을 하기 표 4와 같이 1일 동안 처리하고 인큐베이션 하였다. 인큐베이션 후 CCK 방법을 이용하여 세포의 활성 증진 정도를 평가하였다. CCK-8을 배양액에 1:10으로 처리하여 1시간동안 인큐베이션 하였다. 1시간 후, 각 well의 흡광도(absorbance)를 450nm으로 측정하였다. 모든 실험들은 3번씩 반복되었으며 흡광도 값의 평균을 계산하였다. 상기 결과들은 대조군을 100으로 하고 그에 비한 처리군의 퍼센트로 표현되었다.Human-derived dermal papilla cells (DPCs) were purchased from Promocell. The DPCs were grown in DMEM (Hyclone Inc, UT, USA) containing 5% fetal bovine serum (FBS; Gibco, NY, USA), 100 units/mL of penicillin, and 100 μg/mL of streptomycin at 37°C and 5% CO 2 . Cultured under conditions. 3,000 cells/well of cultured DPCs were dispensed into a 96-well plate and cultured for 24 h under 0.1% serum conditions. Afterwards, the cultured cells were treated with DMSO (vehicle) diluted 1:1000 in serum-free DMEM as a control group, minoxidil 2 ㎍/㎖ as a positive control group, a mixture of adenosine, D-panthenol, and niacinamide, and a mixture of adenosine, D-panthenol, and niacinamide, as well as a mixture of Houttuynia cordata extract and Houttuynia cordata. One or more of the extract, zinc pyrithione, and salicylic acid as shown in Table 4 below. Treated and incubated for 1 day. After incubation, the degree of cell activity enhancement was evaluated using the CCK method. CCK-8 was added to the culture medium at a ratio of 1:10 and incubated for 1 hour. After 1 hour, the absorbance of each well was measured at 450 nm. All experiments were repeated three times and the average of the absorbance values was calculated. The results were expressed as a percentage of the treatment group compared to the control group as 100.
상기 표 4에 개시된 결과를 볼 때, 아데노신, D-판테놀 및 니아신아미드의 혼합물에 하수오 추출물, 어성초 추출물, 징크피리치온, 살리실산 중 1종 이상을 추가로 포함하여 처리하는 경우, 모유두 세포 활성능 증진에 현저한 시너지 효과가 발생함을 확인하였다.Looking at the results disclosed in Table 4 above, when the mixture of adenosine, D-panthenol, and niacinamide is further treated with one or more of Hewlett-Packard extract, Houttuynia cordata extract, zinc pyrithione, and salicylic acid, the dermal papilla cell activation ability It was confirmed that a significant synergistic effect occurred in enhancement.
실험예 2: 모유두 세포 미토콘드리아 활성 촉진 효과Experimental Example 2: Effect of promoting mitochondrial activity in hair papilla cells
인간 유래 모유두 세포(dermal papilla cells, DPCs)는 프로모셀사에서 구입하였다. 상기 DPCs을 5% 우태아 혈청(FBS; Gibco, NY, USA), 페니실린100 unit/mL 및 스트렙토마이신 100 ㎍/mL이 포함된 DMEM(Hyclone Inc, UT, USA)에서 37℃ 및 5% CO2 조건하에 배양하였다. 배양한 DPCs 3,000 cells/well을 96-well 플레이트에 분주한 뒤, 0.1% 혈청 조건에서 24h 동안 배양하였다. 그 후, 배양한 세포에 무혈청 DMEM에 1:1000으로 희석한 DMSO(vehicle)을 대조군으로, 미녹시딜 2 ㎍/㎖을 양성대조군으로, 아데노신, D-판테놀, 니아신아미드의 혼합물에 하수오 추출물, 어성초 추출물, 징크피리치온, 살리실산 중 1종 이상을 하기 표 5와 같이 1일 동안 처리하고 인큐베이션 하였다. 인큐베이션 후 JC-1 방법을 이용하여 세포의 증식 정도를 평가하였다. JC-1을 배양액에 1:100으로 처리하여 1시간 동안 인큐베이션 하였다. 1시간 후, 각 well의 형광(fluorescence)을 590nm 및 530nm으로 측정하였다. 모든 실험들은 3번씩 반복되었으며 형광 값의 평균을 계산하였다. 상기 결과들은 대조군을 100으로 하고 그에 비한 처리군의 퍼센트로 표현되었다.Human-derived dermal papilla cells (DPCs) were purchased from Promocell. The DPCs were grown in DMEM (Hyclone Inc, UT, USA) containing 5% fetal bovine serum (FBS; Gibco, NY, USA), 100 units/mL of penicillin, and 100 μg/mL of streptomycin at 37°C and 5% CO 2. Cultured under conditions. 3,000 cells/well of cultured DPCs were dispensed into a 96-well plate and cultured for 24 h under 0.1% serum conditions. Afterwards, the cultured cells were treated with DMSO (vehicle) diluted 1:1000 in serum-free DMEM as a control group, minoxidil 2 ㎍/㎖ as a positive control group, a mixture of adenosine, D-panthenol, and niacinamide, and a mixture of adenosine, D-panthenol, and niacinamide, as well as extract from Houttuynia cordata. One or more of the extract, zinc pyrithione, and salicylic acid as shown in Table 5 below. Treated and incubated for 1 day. After incubation, the degree of cell proliferation was evaluated using the JC-1 method. JC-1 was added to the culture medium at 1:100 and incubated for 1 hour. After 1 hour, the fluorescence of each well was measured at 590nm and 530nm. All experiments were repeated three times and the average of fluorescence values was calculated. The results were expressed as a percentage of the treatment group compared to the control group as 100.
상기 표 5에 개시된 결과를 볼 때, 아데노신, D-판테놀 및 니아신아미드의 혼합물에 하수오 추출물, 어성초 추출물, 징크피리치온, 살리실산 중 1종 이상을 추가로 포함하여 처리하는 경우, 모유두 세포 미토콘드리아 활성 증진에 현저한 시너지 효과가 발생함을 확인하였다.Looking at the results disclosed in Table 5 above, when the mixture of adenosine, D-panthenol, and niacinamide is further treated with one or more of Hewlett-Packard extract, Houttuynia cordata extract, zinc pyrithione, and salicylic acid, the mitochondrial activity of hair papilla cells It was confirmed that a significant synergistic effect occurred in enhancement.
실험예 3: 모유두 세포 활성 신호(Wnt/β-카테닌) 조절 효과Experimental Example 3: Effect of regulating dermal papilla cell activation signal (Wnt/β-catenin)
일반적으로 모유두에서 활성화 되는 Wnt/β-카테닌 신호는 모발의 성장주기 중 퇴행기에서 활성기로 넘어올 때, 즉 모발이 자라기 시작할 때부터 모발 생장이 일어나는 활성기 동안에 걸쳐 일어난다. 휴지기 및 퇴행기에는 Wnt/β-카테닌 신호가 약해지거나 없어지게 되어 모낭이 퇴화하며 모발이 빠지는 현상이 일어난다. 따라서, 본 개시의 아데노신, D-판테놀, 니아신아미드의 혼합물에 하수오 추출물, 어성초 추출물, 징크피리치온, 살리실산 중 1종 이상 처리군이 Wnt/β-카테닌 신호 증폭에 얼마나 기여하는지 본 실험을 통해 확인하였다.In general, the Wnt/β-catenin signal activated in the hair papilla occurs when the hair goes from the catagen phase to the active phase during the hair growth cycle, that is, from the beginning of hair growth to the active phase when hair growth occurs. During the telogen and catagen phases, Wnt/β-catenin signaling weakens or disappears, causing hair follicles to degenerate and hair loss to occur. Therefore, through this experiment, how much the group treated with a mixture of adenosine, D-panthenol, and niacinamide, and one or more of Houttuynia cordata extract, zinc pyrithione, and salicylic acid in the mixture of the present disclosure contributes to the amplification of the Wnt/β-catenin signal Confirmed.
Wnt/β-카테닌 신호를 증폭시키는 양성대조군으로는 wnt3a 단백질을 이용하였으며, 음성대조군으로는 DMSO를 사용하였다. 배양 96-well plate에 Wnt Reporter HEK293A 세포 3 x 104를 각 well에 시딩(seeding) 후 본 개시의 아데노신, D-판테놀, 니아신아미드의 혼합물에 하수오 추출물, 어성초 추출물, 징크피리치온, 살리실산 중 1종 이상을 하기 표 6과 같이 처리하였다. 그 다음 Promega사의 Luciferase assay kit(E1960)을 이용하여 reporter assay를 진행하였다. 제조사의 실험방법을 따라서 진행하였고, luminometer Victor(PerkinElmer, Waltham, Massachusetts, USA)를 이용하여 Wnt/β-카테닌 프로모터 활성도를 측정하였다.Wnt3a protein was used as a positive control to amplify the Wnt/β-catenin signal, and DMSO was used as a negative control. In a 96-well culture plate, 3 One or more types were treated as shown in Table 6 below. Next, a reporter assay was performed using Promega's Luciferase assay kit (E1960). The experiment was performed according to the manufacturer's test method, and Wnt/β-catenin promoter activity was measured using a luminometer Victor (PerkinElmer, Waltham, Massachusetts, USA).
상기 표 6에 개시된 결과를 볼 때, 아데노신, D-판테놀 및 니아신아미드의 혼합물에 하수오 추출물, 어성초 추출물, 징크피리치온, 살리실산 중 1종 이상을 추가로 포함하여 처리하는 경우, Wnt/β-카테닌 신호전달계의 활성을 시너지적으로 증진시킴을 확인하였다. Wnt/β-카테닌 신호는 모낭줄기세포의 모발 성장 촉진 신호이므로, 상기 실험 결과로부터 본 개시의 조성물이 발모 촉진에 현저한 상승 효과를 나타냄을 알 수 있다.Looking at the results disclosed in Table 6 above, when the mixture of adenosine, D-panthenol, and niacinamide is further treated with one or more of Houttuynia cordata extract, Houttuynia cordata extract, zinc pyrithione, and salicylic acid, Wnt/β- It was confirmed that it synergistically enhances the activity of the catenin signaling system. Since the Wnt/β-catenin signal is a hair growth promoting signal of hair follicle stem cells, it can be seen from the above experimental results that the composition of the present disclosure exhibits a significant synergistic effect in promoting hair growth.
실험예 4: 탈모 치료 또는 발모 촉진용 조성물 1(헤어토닉)의 발모 효과Experimental Example 4: Hair growth effect of composition 1 (hair tonic) for treating hair loss or promoting hair growth
모발의 수가 정상에 비해 현저히 적거나 탈모 증상이 있는 모발이 약한 남녀 총 70명을 대상으로 본 발명의 탈모 치료 또는 발모 촉진용 조성물 1(헤어토닉)의 발모 효과를 실험하였다. 상기 남녀 총 70명을 10명씩 7개 그룹으로 나누어 비교예 1, 2 및 실시예 1 내지 5를 사용하였으며, 1주에 5회씩 6개월 동안 모발 및 두피에 사용하였다. 사용 후 임상사진 촬영을 통한 연구자 평가와 포토트리코그램을 통한 평가를 진행하였다. 임상 사진을 통한 연구자 평가는 도포 2, 6개월 뒤 비교예와 실시예에 대해 ‘good’, ‘slight’, 또는 ‘no change’의 3개 항목으로 평가하였다 (Good: 50%~75% 호전됨, Slight: 25%~50% 호전됨, No change: 무변화). 포토트리코그램을 통한 단위면적당 모발의 개수와 평균 모발의 두께에 대한 평가는 도포 6개월 뒤 비교예 및 실시예에 대해 측정하였으며, 그 결과를 표 7에 나타내었다.The hair growth effect of Composition 1 (hair tonic) for treating hair loss or promoting hair growth of the present invention was tested on a total of 70 men and women with weak hair who had significantly less hair than normal or had hair loss symptoms. A total of 70 men and women were divided into 7 groups of 10 each and used Comparative Examples 1 and 2 and Examples 1 to 5, and were used on the hair and scalp 5 times a week for 6 months. After use, researcher evaluation was conducted through clinical photography and phototricogram. The researcher's evaluation through clinical photographs was based on three items: 'good', 'slight', or 'no change' for comparative examples and examples 2 and 6 months after application (Good: 50% to 75% improvement, Slight: 25%~50% improvement, No change: No change). Evaluation of the number of hairs per unit area and average hair thickness through phototricogram was measured for comparative examples and examples 6 months after application, and the results are shown in Table 7.
상기 표 7에 개시된 결과를 볼 때, 아데노신, D-판테놀 및 니아신아미드의 혼합물을 포함하여 처리하는 경우, 단위면적당 모발 개수 및 평균 모발 두께가 향상됨을 확인하였다. 특히, 본 개시에 따라 아데노신, D-판테놀 및 니아신아미드를 특정한 중량비로 혼합하여 처리하는 경우, 단위면적당 모발 개수 및 평균 모발 두께 향상 효과가 현저하게 증진됨을 확인하였다.Looking at the results disclosed in Table 7, it was confirmed that when treated with a mixture of adenosine, D-panthenol, and niacinamide, the number of hairs per unit area and the average hair thickness were improved. In particular, it was confirmed that when adenosine, D-panthenol, and niacinamide were mixed and treated at a specific weight ratio according to the present disclosure, the effect of improving the number of hairs per unit area and the average hair thickness was significantly improved.
실험예 5: 탈모 치료 또는 발모 촉진용 조성물 2(헤어토닉)의 발모 효과Experimental Example 5: Hair growth effect of composition 2 (hair tonic) for treating hair loss or promoting hair growth
모발의 수가 정상에 비해 현저히 적거나 탈모 증상이 있는 모발이 약한 남녀 총 60명을 대상으로 본 발명의 탈모 치료 또는 발모 촉진용 조성물 2(헤어토닉)의 발모 효과를 실험하였다. 상기 남녀 총 60명을 10명씩 6개 그룹으로 나누어 비교예 1 및 실시예 6 내지 9를 사용하였으며, 1주에 5회씩 6개월 동안 모발 및 두피에 사용하였다. 사용 후 임상사진 촬영을 통한 연구자 평가와 포토트리코그램을 통한 평가를 진행하였다. 임상 사진을 통한 연구자 평가는 도포 2, 6개월 뒤 비교예와 실시예에 대해 ‘good’, ‘slight’, 또는 ‘no change’의 3개 항목으로 평가하였다 (Good: 50%~75% 호전됨, Slight: 25%~50% 호전됨, No change: 무변화). 포토트리코그램을 통한 단위면적당 모발의 개수와 평균 모발의 두께에 대한 평가는 도포 6개월 뒤 비교예 및 실시예에 대해 측정하였으며, 그 결과를 표 8에 나타내었다.The hair growth effect of composition 2 (hair tonic) for hair loss treatment or hair growth promotion of the present invention was tested on a total of 60 men and women with weak hair who had significantly less hair than normal or had hair loss symptoms. A total of 60 men and women were divided into 6 groups of 10 each and used Comparative Example 1 and Examples 6 to 9, and were used on the hair and scalp 5 times a week for 6 months. After use, researcher evaluation was conducted through clinical photography and phototricogram. The researcher's evaluation through clinical photographs was based on three items: 'good', 'slight', or 'no change' for comparative examples and examples 2 and 6 months after application (Good: 50% to 75% improvement, Slight: 25%~50% improvement, No change: No change). Evaluation of the number of hairs per unit area and average hair thickness through phototricogram was measured for comparative examples and examples 6 months after application, and the results are shown in Table 8.
상기 표 8에 개시된 결과를 볼 때, 실시예 6 내지 9와 같이 아데노신, D-판테놀 및 니아신아미드의 혼합물에 하수오 추출물, 어성초 추출물, 징크피리치온, 살리실산 중 1종 이상을 추가로 포함하여 처리하는 경우, 단위면적당 모발 개수 및 평균 모발 두께가 실시예 1 내지 5에 비해 현저하게 증가되어, 탈모 방지 및 발모 촉진에 현저한 시너지 효과를 나타냄을 확인하였다.Considering the results disclosed in Table 8, as in Examples 6 to 9, the mixture of adenosine, D-panthenol, and niacinamide was treated by additionally including one or more of Hewlett-Packard extract, Houttuynia cordata extract, zinc pyrithione, and salicylic acid. In this case, it was confirmed that the number of hairs per unit area and the average hair thickness were significantly increased compared to Examples 1 to 5, showing a significant synergy effect in preventing hair loss and promoting hair growth.
상기 헤어토닉 또는 헤어로션과 같은 제형예는 본 개시의 탈모 방지 또는 발모 촉진용 조성물의 일 예시일 뿐, 본 개시의 조성물의 범위가 이들 제형만으로 한정되지 않는다는 것은 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자에게 자명할 것이다.Formulation examples such as hair tonic or hair lotion are only examples of compositions for preventing hair loss or promoting hair growth of the present disclosure, and the scope of the composition of the present disclosure is not limited to these formulations, as is known in the art to which the present invention pertains. It will be self-evident to those with knowledge.
Claims (12)
하수오 추출물, 어성초 추출물, 징크피리치온 및 살리실산으로 이루어진 군에서 선택된 어느 하나 이상을 유효성분으로 포함하며,
상기 혼합물의 중량비는 1 : 0.3~5 : 0.2~8 (아데노신:D-판테놀:니아신아미드)인 탈모 방지 또는 발모 촉진용 조성물.A mixture of adenosine, D-panthenol and niacinamide; and
Contains as an active ingredient at least one selected from the group consisting of Houttuynia cordata extract, Houttuynia cordata extract, zinc pyrithione, and salicylic acid,
A composition for preventing hair loss or promoting hair growth wherein the weight ratio of the mixture is 1:0.3~5:0.2~8 (adenosine:D-panthenol:niacinamide).
하수오 추출물, 어성초 추출물, 징크피리치온 및 살리실산으로 이루어진 군에서 선택된 어느 하나 이상을 유효성분으로 포함하며,
상기 혼합물의 중량비는 1 : 0.3~5 : 0.2~8 (아데노신:D-판테놀:니아신아미드)인 모발용 조성물.A mixture of adenosine, D-panthenol and niacinamide; and
Contains as an active ingredient at least one selected from the group consisting of Houttuynia cordata extract, Houttuynia cordata extract, zinc pyrithione, and salicylic acid,
A composition for hair where the weight ratio of the mixture is 1:0.3~5:0.2~8 (adenosine:D-panthenol:niacinamide).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20200086878 | 2020-07-14 | ||
KR1020200086878 | 2020-07-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20220008790A KR20220008790A (en) | 2022-01-21 |
KR102675966B1 true KR102675966B1 (en) | 2024-06-17 |
Family
ID=79555640
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020210092451A KR102675966B1 (en) | 2020-07-14 | 2021-07-14 | Composition for preventing hair loss and promoting hair growth |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP2023534287A (en) |
KR (1) | KR102675966B1 (en) |
CN (1) | CN116209425A (en) |
WO (1) | WO2022015055A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102428299B1 (en) | 2022-02-14 | 2022-08-02 | 주식회사 아이두젠 | Composition for preventing hair loss or promoting hair growth, comprising extracts of Stewartia pseudocamellia |
KR20240063217A (en) | 2022-10-28 | 2024-05-10 | 헤르바바이오(주) | Method for manufacturing of fermented herbal solution for promoting hair and herbal fermented solution prepared accordingly |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101445553B1 (en) | 2013-02-27 | 2014-09-29 | 케일럽 멀티랩 (주) | Composition with effect on hair growth |
KR101607437B1 (en) * | 2015-08-19 | 2016-04-04 | 주식회사 성보네츄럴시스템 | Composition for Preventing Lose of Hair Containing Hydrolyzed Complex Amino Acid and Tonic, Shampoo and Treatments Thereof |
KR102054160B1 (en) * | 2017-10-10 | 2019-12-10 | 유씨엘 주식회사 | Cosmetic composition for preventing scalp aging and hair loss |
KR102102578B1 (en) * | 2019-06-26 | 2020-04-21 | 코스맥스 주식회사 | Cosmetic composition for strengthening hair bulb comprising mixture of 18β-Glycyrrhetic acid, D-panthenol and Menthol as effective component |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100992565B1 (en) * | 2005-10-17 | 2010-11-08 | (주)아모레퍼시픽 | Topical preparations for hair growth |
KR102006950B1 (en) * | 2013-12-09 | 2019-08-02 | 주식회사 엘지생활건강 | Cosmetics compositions for hair growth promoter |
KR102090008B1 (en) * | 2019-01-30 | 2020-03-18 | 주식회사 리더스코스메틱 | Cosmetic Composition for Preventing Hair Loss Containing Plumcot Extract |
-
2021
- 2021-07-14 KR KR1020210092451A patent/KR102675966B1/en active IP Right Grant
- 2021-07-14 WO PCT/KR2021/009057 patent/WO2022015055A1/en active Application Filing
- 2021-07-14 JP JP2023503031A patent/JP2023534287A/en active Pending
- 2021-07-14 CN CN202180060665.XA patent/CN116209425A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101445553B1 (en) | 2013-02-27 | 2014-09-29 | 케일럽 멀티랩 (주) | Composition with effect on hair growth |
KR101607437B1 (en) * | 2015-08-19 | 2016-04-04 | 주식회사 성보네츄럴시스템 | Composition for Preventing Lose of Hair Containing Hydrolyzed Complex Amino Acid and Tonic, Shampoo and Treatments Thereof |
KR102054160B1 (en) * | 2017-10-10 | 2019-12-10 | 유씨엘 주식회사 | Cosmetic composition for preventing scalp aging and hair loss |
KR102102578B1 (en) * | 2019-06-26 | 2020-04-21 | 코스맥스 주식회사 | Cosmetic composition for strengthening hair bulb comprising mixture of 18β-Glycyrrhetic acid, D-panthenol and Menthol as effective component |
Also Published As
Publication number | Publication date |
---|---|
KR20220008790A (en) | 2022-01-21 |
JP2023534287A (en) | 2023-08-08 |
WO2022015055A1 (en) | 2022-01-20 |
CN116209425A (en) | 2023-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101196523B1 (en) | Composition for promoting hair growth comprising fermented oriental medicine extract | |
JP2024069595A (en) | Composition for preventing hair loss or promoting hair growth | |
KR102675966B1 (en) | Composition for preventing hair loss and promoting hair growth | |
KR102719515B1 (en) | Composition for Preventing Hair Loss or Promoting Hair Growth | |
KR101985356B1 (en) | Composition for skin external application containing fermented soybean extract | |
KR102063697B1 (en) | Composition for promoting the hair growth comprising escin | |
KR102369387B1 (en) | Cosmetic Composition for prevention of depilation or improvement of hair growth | |
KR101744889B1 (en) | Composition for Anti-oxidation, Whitening and Wrinkles protection | |
KR20150030095A (en) | Composition for improving condition of hair and scalp containing Panax ginseng extract and Green tea extract | |
KR102708620B1 (en) | Composition for preventing hair loss and promoting hair growth | |
KR102537521B1 (en) | Composition for preventing hair loss and promoting hair growth | |
KR101438332B1 (en) | Composition for preventing hair loss or promoting hair growth comprising forsythiaside-A | |
KR101177500B1 (en) | Hair growth stimulating composition | |
JP2006045157A (en) | Hair tonic | |
CN116096344A (en) | Composition for preventing alopecia or promoting hair growth | |
KR20220162555A (en) | Composition for preventing hair loss and promoting hair growth comprising Gypsophila paniculata | |
CN114929239B (en) | Composition for preventing alopecia and promoting hair growth | |
KR102074314B1 (en) | Composition for Preventing Hair Loss or Promoting Hair Growth | |
KR102052517B1 (en) | Composition for improving condition of hair and scalp containing Panax ginseng polysaccharides and Green tea polysaccharides | |
JP5864186B2 (en) | Hair growth promoter | |
KR20220130708A (en) | Composition for preventing hair loss and promoting hair growth | |
KR20210082071A (en) | Composition for preventing hair loss and promoting hair growth | |
KR20180108254A (en) | Composition for skin improvement containing parishin A | |
KR102000934B1 (en) | Cosmetic or pharmaceutical composition for promoting hair growth containing Dehydroandrographolide | |
KR102509285B1 (en) | Composition for promoting the hair growth comprising Alisol B-23-acetate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |